SPONSOR
The First Affiliated Hospital of Soochow University
Total Trials
17
Recruiting
17
Phases
Phase 2, Phase 1, Phase 1, Phase 2, Phase 3
Conditions studied: Systemic MastocytosisKIT-D816V MutationAcute Myeloid LeukemiaRelapsed/Refractory Peripheral T-cell LymphomaEarly Gastric CancerAcute LeukemiaKMT2A Rearrangements or NPM1 Mutations Acute LeukemiaRelapsed or Refractory Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaAplastic Anaemia
The First Affiliated Hospital of Soochow University is a clinical research sponsor with 17 registered studies on ClinicalTrials.gov, of which 17 are actively recruiting participants. Research covers conditions including Systemic Mastocytosis, KIT-D816V Mutation, Acute Myeloid Leukemia, Relapsed/Refractory Peripheral T-cell Lymphoma.
The trial portfolio spans Phase 2, Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — The First Affiliated Hospital of Soochow University
How many clinical trials has The First Affiliated Hospital of Soochow University sponsored?
ClinicalMetric currently tracks 17 clinical trials sponsored by The First Affiliated Hospital of Soochow University, of which 17 are actively recruiting participants. These trials cover conditions including Systemic Mastocytosis, KIT-D816V Mutation, Acute Myeloid Leukemia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does The First Affiliated Hospital of Soochow University research focus on?
The First Affiliated Hospital of Soochow University clinical trials span Systemic Mastocytosis, KIT-D816V Mutation, Acute Myeloid Leukemia, Relapsed/Refractory Peripheral T-cell Lymphoma, Early Gastric Cancer, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a The First Affiliated Hospital of Soochow University clinical trial?
To participate in a The First Affiliated Hospital of Soochow University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all The First Affiliated Hospital of Soochow University trials with current recruitment status updated daily.
Clinical Trials by The First Affiliated Hospital of Soochow University
NCT07562542
Recruiting
Peripheral Blood KIT-D816V Mutation in Adult Systemic Mastocytosis
Systemic Mastocytosis
NCT05657639 Phase 2
Recruiting
CAV Regimen for R/R AML
Acute Myeloid Leukemia
NCT05182957 Phase 2
Recruiting
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Relapsed/Refractory Peripheral T-cell Lymphoma
NCT07551466
Recruiting
AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
Early Gastric Cancer
NCT07270770 Phase 1
Recruiting
BY002 IIT Study in R/R Acute Leukemia
Acute Leukemia
NCT06879847
Recruiting
A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
Relapsed or Refractory Acute Myeloid Leukemia
NCT06507514 Phase 1
Recruiting
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
B-cell Acute Lymphoblastic Leukemia
NCT07499284
Recruiting
A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
Aplastic Anaemia
NCT05772273
Recruiting
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
Acute Myeloid Leukemia
NCT07028073 Phase 1, Phase 2
Recruiting
A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia
Acute Myeloid Leukemia With T(8;21)(Q22;Q22)
NCT07463651 Phase 3
Recruiting
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Acute Myeloid Leukemia (AML)
NCT05376111 Phase 2
Recruiting
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
T-cell Acute Lymphoblastic Leukemia
NCT05571774
Recruiting
Construction of a Database for TTP
TTP - Thrombotic Thrombocytopenic Purpura
NCT07589790
Recruiting
Effect of VR-MBCT in Chronic Nonspecific Low Back Pain
Chronic Non-specific Low Back Pain
NCT06682156
Recruiting
Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
Newly Diagnosed Multiple Myeloma
NCT07559695
Recruiting
A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT
Menin Inhibitors
NCT07400341 Phase 2
Recruiting
Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
MDS (Myelodysplastic Syndrome)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology